Publications
Search by subject
Anemia
X-linked sideroblastic anaemia due to ALAS₂ mutations in the Netherlands: a disease in disguiseDonker AE, Raymakers RA, Nieuwenhuis HK, Coenen MJ, Janssen MC, MacKenzie MA, Brons PP, Swinkels DW. Neth J Med 2014;72(4):210-7.
Hepcidin
Prediction of human iron bioavailability using rapid c-ELISAs for human plasma hepcidinStoffel NU, Zeder C, Fort E, Swinkels DW, Zimmermann MB, Moretti D. Clin Chem Lab Med 2017;55(8):1186-1192.
Iron Refractory Iron Deficiency Anemia (IRIDA): A heterogeneous disease that is not always iron refractoryDonker, Schaap, Novotny, Smeets, Peters, van den Heuvel, Raphael, Rijneveld, Appel, Vlot, Versluijs, van Gelder, Granzen, Janssen, Rennings, van de Veerdonk, Brons, Bakkeren, Nijziel, Vlasveld, Swinkels. Am J Hematol 2016. In press
Toward Worldwide Hepcidin Assay Harmonization: Identification of a Commutable Secondary Reference Material.van der Vorm LN, Hendriks, Laarakkers, Klaver, Armitage, Bamberg, Geurts-Moespot, Girelli, Herkert, Itkonen, Konrad, Tomosugi, Westerman, Bansal, Campostrini, Drakesmith, Fillet, Olbina, Pasricha, Pitts, Sloan, Tagliaro, Weykamp, Swinkels
Hepcidin in the diagnosis of iron disordersGirelli D, Nemeth E, Swinkels DW. Blood 2016;127(23):2809-13
Underestimation of hepcidin concentration by time of flight mass spectrometry and competitive ELISA in hepcidin p.Gly71Asp heterozygotesvan der Vorm LN, van Meijel LJ, Lips J, Galesloot TE, Laarakkers CM, Swinkels DW. Clin Chem Lab Med 2015 [Epub ahead of print].
Hematologic parameters predicting a response to oral iron therapy in chronic inflammationvan Santen S, de Mast Q, Oosting JD, van Ede A, Swinkels DW, van der Ven AJ. Haematologica 2014;99(9):e171-3.
Engineered human lipocalin as an antibody mimetic: application to analysis of the small peptide hormone hepcidinGrebenchtchikov N, Geurts-Moespot AJ, Trentmann S, Andersen N, Bel Aiba RS, Allersdorfer A, Laarakkers CM, Sweep FC, Tjalsma H, Hohlbaum AM, Swinkels DW. Clin Chem 2014;60(6):897-9.
Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoformLaarakkers CM, Wiegerinck ET, Klaver S, Kolodziejczyk M, Gille H, Hohlbaum AM, Tjalsma H, Swinkels DW. PLoS One 2013;8(10):e75518.
Second round robin for plasma hepcidin methods: first steps toward harmonizationKroot JJ, van Herwaarden AE, Tjalsma H, Jansen RT, Hendriks JC, Swinkels DW. Am J Hematol 2012;87(10):977-83.
Mass spectrometry analysis of hepcidin peptides in experimental mouse modelsTjalsma H, Laarakkers CM, van Swelm RP, Theurl M, Theurl I, Kemna EH, van der Burgt YE, Venselaar H, Dutilh BE, Russel FG, Weiss G, Masereeuw R, Fleming RE, Swinkels DW. PLoS One 2011;6(3):e16762.
Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemiavan Santen S, van Dongen-Lases EC, de Vegt F, Laarakkers CM, van Riel PL, van Ede AE, Swinkels DW. Arthritis Rheum 2011;63(12):3672-80.
Hepcidin in human iron disorders: diagnostic implicationsKroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Clin Chem 2011;57(12):1650-69.
Serum hepcidin: reference ranges and biochemical correlates in the general populationGalesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, Wetzels JF, Kiemeney LA, Sweep FC, den Heijer M, Swinkels DW. Blood 2011;117(25):e218-25.
Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disordersKroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, Peters HP, van Dongen-Lases E, Wetzels JF, Sweep FC, Tjalsma H, Swinkels DW. Clin Chem 2010;56(10):1570-9.
A novel immunological assay for hepcidin quantification in human serumKoliaraki V, Marinou M, Vassilakopoulos TP, Vavourakis E, Tsochatzis E, Pangalis GA, Papatheodoridis G, Stamoulakatou A, Swinkels DW, Papanikolaou G, Mamalaki A. PLoS One 2009;4(2):e4581.
High-sensitive radioimmunoassay for human serum hepcidinGrebenchtchikov N, Geurts-Moespot AJ, Kroot JJ, den Heijer M, Tjalsma H, Swinkels DW, Sweep FG. Br J Haematol 2009;146(3):317-25.
Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardizationKroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, Hider RC, Koliaraki V, Mamalaki A, Olbina G, Tomosugi N, Tselepis C, Ward DG, Ganz T, Hendriks JC, Swinkels DW. Haematologica 2009;94(12):1748-52.
Hepcidin: from discovery to differential diagnosisKemna EH, Tjalsma H, Willems HL, Swinkels DW. Haematologica 2008;93(1):90-7.
Advances in quantitative hepcidin measurements by time-of-flight mass spectrometrySwinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H. PLoS One 2008;3(7):e2706.
Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implicationsKemna EH, Tjalsma H, Podust VN, Swinkels DW. Clin Chem 2007;53(4):620-8.
Novel urine hepcidin assay by mass spectrometryKemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D. Blood 2005;106(9):3268-70.
LPI/NTBI
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesde Swart, Reiniers, Bagguley, van Marrewijk, Bowen, Hellström-Lindberg, Tatic, Symeonidis, Huls, Cermak, van de Loosdrecht, Garelius, Culligan, Macheta, Spanoudakis, Panagiotidis, Krejci, Blijlevens, Langemeijer, Droste, Swinkels, Smith, de Witte, EUMDS
Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy VolunteersPratt RD, Swinkels DW, Ikizler, Gupta. J Clin Pharmacol 2016. In press
Catalytic Iron and Acute Kidney InjuryLeaf DE, Swinkels DW. Am J Physiol Renal Physiol 2016; In press
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disordersde Swart L, Hendriks JC, van der Vorm LN, Cabantchik ZI, Evans PJ, Hod EA, Brittenham GM, Furman Y, Wojczyk B, Janssen MC, Porter JB, Mattijssen VE, Biemond BJ, MacKenzie MA, Origa R, Galanello R, Hider RC, Swinkels DW. Haematologica 2016;101(1):38-45.
Correlates of hepcidin and NTBI according to HFE status in patients referred to a liver centreRyan E, Ryan JD, Russell J, Coughlan B, Tjalsma H, Swinkels DW, Stewart S, Crowe JP. Acta Haematol 2015;133(2):155-61.
Non-transferrin-bound iron: a promising biomarker in iron overload disordersMaas RP, Voets PJ, de Swart L, Swinkels DW. Ned Tijdschr Geneeskd 2013;157(49):A6258.
Non-transferrin-bound iron is associated with plasma level of soluble intercellular adhesion molecule-1 but not with in vivo low-density lipoprotein oxidationvan Tits LJ, Jacobs EM, Swinkels DW, Lemmers HL, van der Vleuten GM, de Graaf J, Stalenhoef AF. Atherosclerosis 2007;194(1):272-8.
Serum non-transferrin-bound iron and low-density lipoprotein oxidation in heterozygous hemochromatosisvan Tits LJ, Jacobs EM, Swinkels DW, Lemmers HL, van der Vleuten GM, de Graaf J, Stalenhoef AF. Biochem Biophys Res Commun 2006;345(1):371-6.
Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoformJacobs EM, Hendriks JC, van Tits BL, Evans PJ, Breuer W, Liu DY, Jansen EH, Jauhiainen K, Sturm B, Porter JB, Scheiber-Mojdehkar B, von Bonsdorff L, Cabantchik ZI, Hider RC, Swinkels DW. Anal Biochem 2005;341(2):241-50.
DNA
Iron Refractory Iron Deficiency Anemia (IRIDA): A heterogeneous disease that is not always iron refractoryDonker, Schaap, Novotny, Smeets, Peters, van den Heuvel, Raphael, Rijneveld, Appel, Vlot, Versluijs, van Gelder, Granzen, Janssen, Rennings, van de Veerdonk, Brons, Bakkeren, Nijziel, Vlasveld, Swinkels. Am J Hematol 2016. In press
EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH)Porto G, Brissot P, Swinkels DW, Zoller H, Kamarainen O, Patton S, Alonso I, Morris M, Keeney S. Eur J Hum Genet 2016;24(4):479-95.
Microcytic anaemia with low transferrin saturation, increased serum hepcidin and non-synonymous TMPRSS6 variants: not always iron-refractory iron deficiency anaemiaDonker AE, Brons PP, Swinkels DW. Br J Haematol 2015;169(1):150-1.
X-linked sideroblastic anaemia due to ALAS₂ mutations in the Netherlands: a disease in disguiseDonker AE, Raymakers RA, Nieuwenhuis HK, Coenen MJ, Janssen MC, MacKenzie MA, Brons PP, Swinkels DW. Neth J Med 2014;72(4):210-7.
A novel (Leu183Pro-)mutation in the HFE-gene co-inherited with the Cys282Tyr mutation in two unrelated Dutch hemochromatosis patientsSwinkels DW, Venselaar H, Wiegerinck ET, Bakker E, Joosten I, Jaspers CA, Vasmel WL, Breuning MH. Blood Cells Mol Dis 2008;40(3):334-8.
Effect of the new HJV-L165X mutation on penetrance of HFEvan Dijk BA, Kemna EH, Tjalsma H, Klaver SM, Wiegerinck ET, Goossens JP, Slee PH, Breuning MH, Swinkels DW. Blood 2007;109(12):5525-6.
Rapid genotyping of single nucleotide polymorphisms using novel minor groove binding DNA oligonucleotides (MGB probes)de Kok JB, Wiegerinck ET, Giesendorf BA, Swinkels DW. Hum Mutat 2002;19(5):554-9.
Oxidative stress
The effect of iron loading and iron chelation on the innate immune response and subclinical organ injury during human endotoxemia: a randomized trialvan Eijk LT, Heemskerk S, van der Pluijm RW, van Wijk SM, Peters WH, van der Hoeven JG, Kox M, Swinkels DW, Pickkers P. Haematologica 2014;99(3):579-87.
